Joseph Schwartz
Stock Analyst at Leerink Partners
(4.92)
# 208
Out of 4,382 analysts
1354
Total ratings
52.1%
Success rate
28.1%
Average return
Main Sectors:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterated: Buy | $225 → $305 | $210.45 | +44.93% | 72 | Jun 2, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $24 → $4 | $3.69 | +8.40% | 37 | Jun 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 → $62 | $56.77 | +9.21% | 90 | May 18, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $160 → $120 | $50.43 | +137.95% | 32 | May 15, 2026 | |
| ANTX AN2 Therapeutics | Upgraded: Buy | $1 → $9 | $3.82 | +135.60% | 23 | May 15, 2026 | |
| RNA Atrium Therapeutics | Initiated Coverage: Buy | $25 | $11.80 | +111.86% | 1 | May 15, 2026 | |
| KALV KalVista Pharmaceuticals | Downgraded: Hold | $27 | $26.95 | +0.19% | 48 | Apr 29, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Initiated Coverage: Buy | $27.87 | $8.20 | +239.87% | 1 | Apr 6, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $26 → $25 | $5.73 | +336.30% | 31 | Mar 26, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $15 | $15.75 | -4.76% | 107 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $24.27 | +106.02% | 9 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 | $0.175 | +3,328.57% | 35 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $45.81 | - | 87 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $21.91 | - | 69 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $31.09 | +22.23% | 37 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.84 | - | 50 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $2 | $0.3132 | +538.57% | 31 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $35.59 | - | 49 | Dec 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.70 | +198.51% | 45 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $16 | $15.84 | +1.01% | 52 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $5 → $14 | $10.65 | +31.46% | 29 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 → $60 | $26.45 | +126.84% | 61 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $115 | $59.78 | +92.37% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 | $70.97 | -23.91% | 33 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $94.22 | - | 63 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $32.92 | +167.31% | 45 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.17 | +688.64% | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.41 | +609.22% | 29 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $0.69 | n/a | 29 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.18 | n/a | 19 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $14 | $181.34 | n/a | 1 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $150 → $30 | $5.84 | n/a | 10 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 → $34 | $74.48 | n/a | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $97.38 | n/a | 28 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $349.58 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.18 | n/a | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $31 → $4 | $34.71 | n/a | 16 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $312.37 | n/a | 1 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52.95 | $216.40 | n/a | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $30 | $1.27 | n/a | 2 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 → $23 | $13.54 | n/a | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $12 | $1.50 | n/a | 5 | Sep 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $121 → $126 | $549.87 | n/a | 4 | Apr 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $16.59 | n/a | 11 | Nov 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.077 | n/a | 5 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $6.63 | n/a | 6 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $1.02 | n/a | 1 | Mar 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $664 | $635.45 | n/a | 7 | Oct 26, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $512 → $425 | $195.34 | n/a | 3 | Sep 15, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $8 | $71.48 | n/a | 3 | May 19, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.93 | n/a | 6 | Oct 30, 2013 |
Ascendis Pharma
Jun 2, 2026
Reiterated: Buy
Price Target: $225 → $305
Current: $210.45
Upside: +44.93%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $24 → $4
Current: $3.69
Upside: +8.40%
BioMarin Pharmaceutical
May 18, 2026
Reiterated: Hold
Price Target: $60 → $62
Current: $56.77
Upside: +9.21%
Spruce Biosciences
May 15, 2026
Reiterated: Buy
Price Target: $160 → $120
Current: $50.43
Upside: +137.95%
AN2 Therapeutics
May 15, 2026
Upgraded: Buy
Price Target: $1 → $9
Current: $3.82
Upside: +135.60%
Atrium Therapeutics
May 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $11.80
Upside: +111.86%
KalVista Pharmaceuticals
Apr 29, 2026
Downgraded: Hold
Price Target: $27
Current: $26.95
Upside: +0.19%
Satellos Bioscience Inc.
Apr 6, 2026
Initiated Coverage: Buy
Price Target: $27.87
Current: $8.20
Upside: +239.87%
Wave Life Sciences
Mar 26, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $5.73
Upside: +336.30%
Sarepta Therapeutics
Mar 25, 2026
Maintained: Hold
Price Target: $15
Current: $15.75
Upside: -4.76%
Mar 25, 2026
Reiterated: Buy
Price Target: $50
Current: $24.27
Upside: +106.02%
Feb 23, 2026
Downgraded: Hold
Price Target: $6
Current: $0.175
Upside: +3,328.57%
Jan 13, 2026
Maintained: Buy
Price Target: n/a
Current: $45.81
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.91
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: $38
Current: $31.09
Upside: +22.23%
Dec 31, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.84
Upside: -
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $2
Current: $0.3132
Upside: +538.57%
Dec 24, 2025
Maintained: Buy
Price Target: n/a
Current: $35.59
Upside: -
Dec 15, 2025
Reiterated: Buy
Price Target: $20
Current: $6.70
Upside: +198.51%
Dec 3, 2025
Downgraded: Hold
Price Target: $12 → $16
Current: $15.84
Upside: +1.01%
Dec 3, 2025
Upgraded: Buy
Price Target: $5 → $14
Current: $10.65
Upside: +31.46%
Nov 10, 2025
Reiterated: Buy
Price Target: $68 → $60
Current: $26.45
Upside: +126.84%
Nov 10, 2025
Initiated Coverage: Buy
Price Target: $115
Current: $59.78
Upside: +92.37%
Oct 16, 2025
Reiterated: Hold
Price Target: $54
Current: $70.97
Upside: -23.91%
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $94.22
Upside: -
Sep 29, 2025
Reiterated: Buy
Price Target: $88
Current: $32.92
Upside: +167.31%
Aug 15, 2025
Reiterated: Buy
Price Target: $25
Current: $3.17
Upside: +688.64%
Aug 7, 2025
Maintained: Buy
Price Target: $10
Current: $1.41
Upside: +609.22%
Aug 12, 2024
Reiterated: Hold
Price Target: $1
Current: $0.69
Upside: n/a
May 7, 2024
Reiterated: Hold
Price Target: $10
Current: $4.18
Upside: n/a
Sep 7, 2023
Maintained: Hold
Price Target: $14
Current: $181.34
Upside: n/a
Aug 18, 2023
Downgraded: Hold
Price Target: $150 → $30
Current: $5.84
Upside: n/a
Feb 3, 2023
Maintained: Hold
Price Target: $40 → $34
Current: $74.48
Upside: n/a
Aug 5, 2022
Reiterated: Buy
Price Target: $30
Current: $97.38
Upside: n/a
Aug 4, 2022
Rated: Hold
Price Target: n/a
Current: $349.58
Upside: n/a
Jul 13, 2022
Maintained: Buy
Price Target: n/a
Current: $6.18
Upside: n/a
Apr 5, 2022
Downgraded: Hold
Price Target: $31 → $4
Current: $34.71
Upside: n/a
May 7, 2021
Downgraded: Sell
Price Target: n/a
Current: $312.37
Upside: n/a
Apr 15, 2021
Maintained: Buy
Price Target: $52.95
Current: $216.40
Upside: n/a
Jan 6, 2021
Downgraded: Hold
Price Target: $5 → $30
Current: $1.27
Upside: n/a
Nov 28, 2018
Initiated Coverage: Buy
Price Target: $37 → $23
Current: $13.54
Upside: n/a
Sep 26, 2017
Maintained: Buy
Price Target: $10 → $12
Current: $1.50
Upside: n/a
Apr 3, 2017
Maintained: Hold
Price Target: $121 → $126
Current: $549.87
Upside: n/a
Nov 13, 2016
Reiterated: Buy
Price Target: n/a
Current: $16.59
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $8
Current: $0.077
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $12 → $14
Current: $6.63
Upside: n/a
Mar 8, 2016
Maintained: Buy
Price Target: $24
Current: $1.02
Upside: n/a
Oct 26, 2015
Reiterated: Buy
Price Target: $664
Current: $635.45
Upside: n/a
Sep 15, 2015
Maintained: Buy
Price Target: $512 → $425
Current: $195.34
Upside: n/a
May 19, 2014
Initiated Coverage: Buy
Price Target: $20 → $8
Current: $71.48
Upside: n/a
Oct 30, 2013
Downgraded: Hold
Price Target: n/a
Current: $13.93
Upside: n/a